Grifols SA (GRFS)
Grifols makes medicines derived from human plasma and diagnostic products for hospitals, clinics and laboratories. It last closed at $8.15 on Nov 20, down 0.61% on the day.
Key Stats
Fiscal 2024Not reported for this period.
From GRFS's SEC filings, latest 20-F for the period ending Dec 31, 2024 (filed Apr 17). Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on GRFS
Technical AnalysisPrices may be delayed
The stock sits between its 20 and 50 day averages. It is 2% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 47). The nearest support is the Pivot S1 at $8.08, and the nearest resistance the swing high (May 27) at $8.18.
| RSI (14) | 46.55 | Middle of its range | Neutral |
| MACD | 0.18 | Below its signal line | Bearish |
| Stochastic | 19.8 | Near the bottom of its range | Oversold |
| ADX (14) | 32.7 | Trending down | |
| Williams %R | -91.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -78.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −3.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.23 | Typical daily range, 2.8% of price |
| RSI (14) | 53.96 | Middle of its range | Neutral |
| MACD | 0.05 | Above its signal line | Bullish |
| Stochastic | 75.8 | Middle of its range | Neutral |
| ADX (14) | 19.1 | No clear trend | |
| Williams %R | -42.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 114.5 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +8.0% | Change over 10 sessions | Bullish |
| ATR (14) | $0.49 | Typical daily range, 6.1% of price |
What happened before
See how GRFS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How GRFS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2011.
Whale Options FlowPrices may be delayed
90DNo whale options trades in GRFS in the last 90 days.
GRFS Institutional Ownership
Full report →- ▲86 buying vs 70 selling
- ▼Shares held by funds -2.1%
- ●Funds holding -1
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 167 | 168 | −0.6% |
| In funds' top 10 | 3 | 3 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 18 / 68 | 17 / 53 | +22.9% |
| Reduced / sold out | 50 / 20 | 68 / 38 | −34.0% |
| Put/call ratio | 0.91 | 0.24 | +284.3% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRFS is in one of them and how their past GRFS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GRFS in an article yet. Here's the latest on the wider market.
GRFS Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Dan GoldmanD · NY | Sell | $1K – $15K | Mar 31, 2023 | Apr 17, 2023 | 17 d |
| Dan GoldmanD · NY | Buy | $1K – $15K | Feb 27, 2023 | Mar 20, 2023 | 21 d |
| Donna ShalalaD · FL | Sell | $1K – $15K | Jun 24, 2019 | Apr 27, 2020 | 308 d |
| Greg GianforteR · MT | Sell | $100K – $250K | Nov 11, 2019 | Dec 23, 2019 | 42 d |
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Grifols SA
Grifols makes medicines derived from human plasma, the liquid part of blood, and sells them to hospitals, clinics and healthcare providers. These therapies treat conditions such as immune deficiencies, hemophilia and emphysema linked to alpha 1 protein deficiency. The company also makes diagnostic tests and instruments for blood banks and clinical laboratories, along with infusion solutions and nutrition products for hospital use. It is based in New York and runs plasma collection centers to supply its manufacturing.
- Headquarters
- New York, NY





